Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 20 entries
The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications.
Massachusetts General Hospital is conducting a research study to develop and assess the feasibility and effect of a web-based, personalized risk-estimation for CD (PRE-Crohn’s) tool on behaviors and biomarkers associated with CD in unaffected first-degree relatives (FDRs) of patients with inflammatory bowel disease.
The primary objective of the registry is to estimate the prevalence of major congenital malformations among pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy.
The primary objective of this research is to evaluate specific and non-specific effects of hypnotherapy.
The secondary objective is to evaluate the efficacy of group-format gut-directed hypnotherapy delivered via telehealth for managing gastrointestinal health.
The objective of the BOOM-IBD2 clinical trial is to evaluate the effectiveness of an investigational nerve stimulation (neuromodulation) device for ulcerative colitis (UC). This treatment involves implanting a small electronic device that delivers mild electrical pulses to a nerve near the tailbone. The study will assess the impact of this therapy on bowel urgency, quality of life, inflammation, and other measures over a 12-month period through a combination of in-person and virtual visits.
To create a high-risk for inflammatory bowel disease research cohort, by enrolling individuals who have a first-degree relative (parent sibling, or child) with inflammatory bowel disease (IBD; including Crohn’s disease, ulcerative colitis, or IBD unclassified/indeterminate colitis), but who do not have one of these diseases themselves.
To monitor behaviors, diet, and biomarkers of IBD in these unaffected first-degree relatives over time, to better understand how to predict and prevent the development of IBD in high-risk individuals.
To determine the effect of dual targeted therapy with an anti-integrin (VDZ) and a JAK inhibitor (TOF) on clinical remission.
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy with Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn’s Disease (CD).
The purpose of this study is to continuously monitor a patient's IBD biomarkers with the non-invasive IBD AWARE® wearable device to determine its effectiveness in monitoring IBD inflammation. We also aim to understand how these inflammatory biomarkers relate to your symptoms. By participating, you'll help us enhance the way we monitor and manage IBD.
The Cimzia Pregnancy Exposure Registry is following pregnant women who have been treated with Cimzia during pregnancy and comparing them to pregnant women who were not exposed to Cimzia. Both groups of women and their babies will be followed up to 1 year after delivery. The goal is to determine the possible effect of Cimzia and the diseases it treats on pregnancy and infant outcomes.
The Featured Study Opportunities page is made possible in part by:
